Biotech · Private company
Aerie Pharmaceuticals
Track this companyFree. Adds Aerie Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials160 recruiting or active
Pipeline programs24From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline24
- 0.003% AR-15512 ophthalmic solutionPhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AR-15512 vehicle ophthalmic solutionPhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Latanoprost Ophthalmic Solution 0.005%Phase 3 · Open-angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- Netarsudil (AR-13324) Ophthalmic Solution 0.02%Phase 3 · Open-angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- PG324 Ophthalmic Solution 0.02%/0.005%Phase 3 · Open-angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- AR-1105-CF1Phase 2 · Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- AR-1105-CF2Phase 2 · Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- AR-13324 Ophthalmic Solution 0.02%Phase 2 · Primary Open Angle Glaucoma or Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- AR-13324 Ophthalmic Solution 0.04%Phase 2 · Primary Open Angle Glaucoma or Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- AR-15512 Ophthalmic SolutionPhase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AR-15512 Ophthalmic Solution VehiclePhase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Netarsudil OphthalmicPhase 2 · Corneal EdemaClinicalTrials.gov · fetched Nov 12, 2026
- Netarsudil Ophthalmic Solution 0.02%Phase 2 · Primary Open Angle Glaucoma or Ocular HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- PG324 Ophthalmic Solution 0.01%Phase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- PG324 Ophthalmic Solution 0.02%Phase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- 0.003% AR-15512 to be administered in both eyesPhase 1 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AR-13324 Ophthalmic Solution, 0.02%Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- AR-13503 42.4 DosePhase 1 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AR-13503 63.6 DosePhase 1 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AR-13503 Implant 10.6 DosePhase 1 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AR-13503 Implant 21.2 DosePhase 1 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle to be administered in both eyesPhase 1 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solutionGlaucomaClinicalTrials.gov · fetched Nov 12, 2026
- Netarsudil Ophthalmic Solution 0.02%Glaucoma, Open-AngleClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512PHASE3 · COMPLETED · started Nov 1, 2022ClinicalTrials.gov NCT05493111 · fetched Nov 12, 2026
- Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)PHASE3 · COMPLETED · started Jul 18, 2022ClinicalTrials.gov NCT05360966 · fetched Nov 12, 2026
- Study Evaluating the Safety and Efficacy of AR-15512PHASE3 · COMPLETED · started May 9, 2022ClinicalTrials.gov NCT05285644 · fetched Nov 12, 2026
- Rocklatan® EvaluationPHASE4 · COMPLETED · started Mar 28, 2022ClinicalTrials.gov NCT05283395 · fetched Nov 12, 2026
- Study Evaluating Techniques for Measuring Tear ProductionPHASE1 · COMPLETED · started Dec 9, 2021ClinicalTrials.gov NCT05497479 · fetched Nov 12, 2026
- A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye DiseasePHASE2 · COMPLETED · started Oct 26, 2020ClinicalTrials.gov NCT04498182 · fetched Nov 12, 2026
- A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal DystrophyPHASE2 · COMPLETED · started Sep 17, 2020ClinicalTrials.gov NCT04498169 · fetched Nov 12, 2026
- A Study Assessing AR-13503 Implant in Subjects With nAMD or DMEPHASE1 · COMPLETED · started Jun 24, 2019ClinicalTrials.gov NCT03835884 · fetched Nov 12, 2026
- Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)PHASE2 · COMPLETED · started Mar 13, 2019ClinicalTrials.gov NCT03739593 · fetched Nov 12, 2026
- Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world SettingPHASE4 · COMPLETED · started Dec 27, 2018ClinicalTrials.gov NCT03808688 · fetched Nov 12, 2026
- Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular HypertensionPHASE2 · COMPLETED · started Nov 15, 2017ClinicalTrials.gov NCT03310580 · fetched Nov 12, 2026
- Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)PHASE2 · COMPLETED · started Oct 20, 2017ClinicalTrials.gov NCT03233308 · fetched Nov 12, 2026
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionPHASE3 · COMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02674854 · fetched Nov 12, 2026
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionPHASE3 · COMPLETED · started Sep 18, 2015ClinicalTrials.gov NCT02558400 · fetched Nov 12, 2026
- Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular PressurePHASE2 · COMPLETED · started Jan 1, 2014ClinicalTrials.gov NCT02057575 · fetched Nov 12, 2026
- Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy VolunteersPHASE1 · COMPLETED · started Nov 1, 2013ClinicalTrials.gov NCT01997879 · fetched Nov 12, 2026